Kandepres

Candesartan cilexetil, the active ingredient in Kandepres, is an Angiotensin II receptor blocker presented as an oral tablet for systemic use. It is prescribed to manage high blood pressure and related cardiovascular conditions in adult patients. By selectively blocking AT1 receptors, it reduces vasoconstriction and aldosterone‑mediated fluid retention, helping to lower blood pressure and protect organ function.

GNH USA supplies Kandepres as a licensed, GDP‑compliant international pharmaceutical product to hospitals, pharmacies and clinics worldwide.

Kandepres (candesartan cilexetil) is used in the management of conditions involving the renin‑angiotensin system. - Hypertension: lowers elevated blood pressure and reduces cardiovascular risk. - Heart failure: improves symptoms and decreases hospitalization rates in patients with reduced ejection fraction. - Diabetic nephropathy: slows progression of kidney damage associated with diabetes.

Candesartan cilexetil may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Upper respiratory tract infection - Diarrhea

Serious or Rare Side Effects: - Hyperkalemia - Acute kidney injury - Angioedema - Severe hypotension

When prescribing candesartan cilexetil, clinicians should consider several safety measures to minimize risk. - Monitor blood pressure: check for excessive hypotension after initiation or dose changes. - Assess renal function: evaluate serum creatinine and eGFR before and during therapy. - Check serum potassium: avoid hyperkalemia, especially in patients on potassium‑sparing diuretics. - Use caution in hepatic impairment: dose adjustments may be required. - Avoid in pregnancy: drug is contraindicated due to fetal toxicity. - Store at ambient temperature: keep below 25°C, protect from moisture and light in original packaging.

Candesartan cilexetil can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant use with ACE inhibitors or aliskiren in diabetes: risk of severe hypotension, hyperkalemia, and renal dysfunction. - Potassium‑supplementing agents or potassium‑sparing diuretics: may cause dangerous hyperkalemia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can reduce antihypertensive effect and impair renal function. - Diuretics (especially thiazides): may enhance hypotensive response. - Lithium: candesartan may increase lithium levels, requiring monitoring.